Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 608.10

Pulse Biosciences, Inc. Price to Sales Ratio (P/S) is 608.10 on January 14, 2025, a 131.32% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Pulse Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is 785.73 on December 04, 2024, which is 29.21% above the current Price to Sales Ratio (P/S).
Pulse Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is 213.69 on April 25, 2024, which is -64.86% below the current Price to Sales Ratio (P/S).
Pulse Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 455.39.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years